PDCD1 and small cell lung carcinoma: In conclusion, anlotinib plus PD‐1/PD‐L1 blockade therapy has shown significant benefits as a second‐line and later‐line therapeutic option for advanced SCLC without causing more serious adverse reactions than chemotherapy.